Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER - Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A - Will play a key role in building and executing Arecor’s ambitious commercialisation and growth plans as pipeline of proprietary and partnered products advances Cambridge, UK, 5 April 2023: Arecor…

Arecor Therapeutics plc (“Arecor” or the “Group”) FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE - Disrupter insulin with potential to be the first ultra-concentrated and ultra-rapid acting insulin available for patients - AT278 aims to significantly improve post prandial glucose control and reduce injection volume and potentially enable fewer injections per day for people with Type 2 diabetes who have high insulin needs - Ultra-concentrated, ultra-rapid acting insulin such as AT278 is critical to development of next…

Contract Research Organizations (CROs) have become vital partners in the drug development process, enabling biotech and pharmaceutical companies to develop and market life-saving drugs. To further understand the supply chain complexities for CROs, Biocair recently conducted a qualitative research study with CRO supply chain professionals. The study involved 45-minute business interviews with supply chain professionals working for CROs. The results of the study have proved instrumental for Biocair in furthering its understanding of the intricacies facing CROs and how logistics play a vital…

Economic data shows uplifting effect on employment across both Knowledge Intensive (KI) and non-KI sectors in the Cambridgeshire and Peterborough region. Cambridge, UK. 4th April 2023: The latest in-depth analysis on the Cambridge city region economy from Cambridge Ahead, produced by the Centre for Business Research (CBR) at the University of Cambridge, shines a spotlight on science and innovation-led job creation that is fuelling a buoyant and resilient corporate economy, and is increasingly having a positive effect on job creation across wider (non-KI) sectors in the wider Cambridgeshire…

NRG Therapeutics Announces International Scientific Advisory Board Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders. The four founding members of NRG’s International SAB are US-based and bring in-depth translational expertise in neuroscience and drug discovery across chemistry, biology and pharmacology…

In a fiercely competitive recruitment market, how do you make your company irresistible to the best tech talent? St John's Innovation Centre, in collaboration with Innovate UK EDGE, Taylor Vinters and tech executive search firm Bailey Fisher, are planning an event that will offer invaluable insight into the ways in which founders of tech businesses can recruit and retain talent effectively. The session will share advice on employee engagement, employment structures, corporate culture/purpose, hybrid working/4 day week, DEI, vacancy marketing and hiring practices while also exploring the…

Pharmaron announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM. This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity. The resulting facility will greatly…

Agility Life Sciences, an award-winning formulation development CDMO based in Nottingham, UK, and Solitek, experts in solid state development services for the pharmaceutical, agrochemical and fine chemical industries based in Barcelona, Spain, have entered into a Strategic Partnership agreement in order to accelerate the pharmaceutical development milestones of their clients. The agreement will see Agility Life Sciences signpost and recommend Solitek’s solid state services to clients, with Solitek reciprocally promoting Agility’s formulation development services. The two organisations have…

As the tide recedes from the recent Spring Budget 2023, we explore what has changed regarding R&D tax incentives and how this may impact the UK’s life sciences and biotech industry. WHAT IS THE BACKGROUND? Before going into detail on the research and development (R&D) tax relief changes announced, it is helpful to recap the background. There are currently two schemes of relief: 1. Designed for small and medium-sized enterprises (SMEs) - consisting of an additional tax deduction combined with a payable credit for loss-makers; and 2. Designed for larger companies and consisting of an R…

Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has been officially presented with the prestigious Queen’s Award for Enterprise for International Trade following significant growth in its export business. Cellomatics is one of just 232 organisations nationally to be recognised with the prominent award, which this year becomes the King’s Award for Enterprise. The company was presented with the award by the Lord Lieutenant of Nottingham, Sir John Peace, on Thursday 23 March at a ceremony hosted at Cellomatics’ Head Office in Colwick. The afternoon event was…